INTRODUCTION
Pax3 is a key regulator of myogenesis during development (Buckingham et al., 2003) . In splotch (Sp) mice, which carry spontaneous mutations in the pax3 locus, limb muscles are absent (Bober et al., 1994) . The formation of these muscles requires Pax3, which has been shown to induce the expression of c-Met, a tyrosine kinase receptor essential for the delamination and migration of muscle progenitor cells (Bladt et al., 1995; Yang et al., 1996) . More recently, it was shown that Pax3 and its close homolog, Pax7, are expressed in a population of myogenic precursor cells that give rise to a population of adult muscle stem cells (Gros et al., 2005; Relaix et al., 2005) . Interestingly, cells that fail to express Pax3 or Pax7 die or switch to another cell fate (Relaix et al., 2005) .
In postnatal myogenesis, Pax3 is transiently expressed during muscle stem cell (''satellite cell'') activation in a highly proliferative intermediate progenitor cell population (Conboy and Rando, 2002) . The association of enhanced Pax3 activity with a highly proliferative state is consistent with aberrant Pax3 expression with tumors bearing skeletal muscle characteristics (Barr, 2001) . In humans, a severe form of alveolar rhabdomyosarcoma (ARMS) is due to a chromosomal translocation t(2; 13) that results in a fusion between the Pax3 gene and the forkhead (FKHR) gene and the generation of a Pax3FKHR fusion protein. This protein consists of the DNA-binding domains of Pax3 fused to the transcription activation domain of FKHR. Pax3FKHR is a powerful gain-of-function mutation (Bennicelli et al., 1999) and is thought to exert its role in ARMS through aberrant regulation of Pax3 target genes (Barr, 2001) .
It is clear that normal muscle development and postnatal myogenesis depend on the timely and coordinated expression of Pax3 and Pax7. In the present study, we investigated the regulation of Pax3 and Pax7 at the protein level, based on evidence of differential responses to inhibition of proteasomal activity. The data presented support the hypothesis that the levels of Pax3, but not Pax7, are regulated by the ubiquitin/proteasome pathway. In addition, the results suggest a unique mechanism of proteasomal degradation involving protein monoubiquitination.
with previous findings (Conboy and Rando, 2002) . The percentage of Pax3 + myogenic progenitors was almost zero initially but increased rapidly, peaking around day 3 ( Figures 1A and 1B) , thus paralleling the appearance of intermediate progenitor cells (Conboy and Rando, 2002) . Pax3 protein then declined to undetectable levels as progenitor cells proliferated and progressed along the myogenic lineage pathway ( Figure 1A ). In established myoblast cultures, Pax3 + cells were rare ( Figure 1A ).
Quantitative RT-PCR analysis showed that Pax3 transcript was nearly undetectable in quiescent satellite cells from hindlimb muscle but was highly induced during satellite cell activation, peaking around day 3. Transcript levels then declined but were maintained at intermediate levels thereafter, even as protein levels declined further (Figures 1A and 1C) . Only when myogenic progenitors were induced to differentiate did the levels of Pax3 transcript fall to undetectable levels ( Figure 1C ). Clearly, a marked discrepancy exists between the levels of Pax3 mRNA and protein during the late stages of the myogenic program, suggesting that Pax3 protein level is regulated posttranscriptionally.
To test for the role of protein degradation in regulating levels of Pax3, we treated cultures of activated satellite cells with the proteasome inhibitor, MG132. This resulted in a more than 3-fold increase in the percentage of Pax3 + cells ( Figure 1D ). Likewise, treatment of myoblast cultures with MG132 resulted in a dose-dependent increase in Pax3 protein level but no change in the level of Pax7 ( Figure 1E ). These results suggest that the decline in Pax3 protein levels during myogenic lineage progression, when Pax7 levels are maintained, is due to selective degradation of Pax3 by the ubiquitin/proteasome system (UPS).
Pax3 Degradation Requires a Functional UPS
To confirm that the degradation of Pax3 was due to the UPS, we used the ts20b cell line, which carries a temperature-sensitive ubiquitin-activating enzyme, E1 (Chowdary et al., 1994) . Pax3 levels were stable at a nonpermissive temperature but declined at a permissive temperature ( Figure S1 ). The control cell line (H38-5) demonstrated Pax3 degradation regardless of the temperature (Figure S1 ). These data show that Pax3 degradation requires a functional UPS.
In Vitro Evidence of UPS-Mediated Degradation of Monoubiquitinated Pax3
To test directly if Pax3 is susceptible to proteasomal degradation, we used a cell-free ubiquitination/proteasome degradation assay (Bloom et al., 2003) . Under a standard condition in which p21 CIP1 that was used as a positive control (Bloom et al., 2003) was rapidly degraded ( Figure S2 ), Pax7 was stable (Figure 2A ), as predicted from the in vivo results ( Figure 1E ). However, in apparent contradiction of the previous results in vivo (Figures 1  and S1 ), Pax3 was unexpectedly stable (Figure 2A ). This apparent paradox of the MG132-sensitive and E1-ligasedependent degradation of Pax3 in vivo with its apparent stability in vitro was resolved when the in vitro assays were carried out in the presence of either methylated ubiquitin (Ub Me ) or mutant ubiquitin containing no lysines . The left panel shows that only monoubiquitinated Pax3 was generated even in the presence of WT Ub, whereas polyubiquitinated forms of p21 CIP1 were clearly generated. As expected, only monoubiquitinated forms of both proteins were detected in the presence of Ub
K0
. Arrows indicate the positions of the native proteins (Pax3 and p21), monoubiquitinated forms (Pax3-Ub 1 and p21-Ub 1 ), and polyubiquitinated forms (Pax3-Ub n and p21-Ub n ). (D) Ubiquitination of 35 S-labeled Pax3 was carried out in the presence of a reaction solution containing 26S proteasome that had been pretreated with either Ub or Ub K0 (both His-tagged) but in the absence of MG132. The proteins were subjected to Nickel-agarose purification. Less monoubiquitinated Pax3 was generated when the reaction mixture was pretreated with WT ubiquitin. Native Pax3 is not present because it is not pulled down by the Nickel-agarose purification. The graph on the right represents the quantitation of monoubiquitinated Pax3 protein normalized to the amount of monoubiquitinated Pax3 protein in reactions pretreated with Ub K0 . (E) The stability of recombinant Pax3 was assessed for 6 or 18 hr in an excess of Ub in a reaction solution containing 26S proteasome that had been pretreated with either Ub or Ub K0 . The amount of Pax3 proteins remaining was determined by immunoblot analysis.
(Ub K0 ), both of which allow monoubiquitination but prevent polyubiquitination (Chau et al., 1989; Hershko et al., 1991) . Under these conditions, Pax3, but not Pax7, underwent rapid proteasomal degradation ( Figures  2B and S3A) . Furthermore, this degradation was inhibited by MG132 ( Figure 2B ). Therefore, in vitro conditions in which protein ubiquitination is limited to monoubiquitination closely resembled the in vivo situation in which Pax3, but not Pax7, was susceptible to proteasomemediated degradation. These findings suggest that one or more components of the assay system that are responsible for ubiquitination and/or degradation of Pax3 may themselves undergo polyubiquitination and degradation in the presence of wild-type (WT) ubiquitin. These results also suggest that a monoubiquitinated form of Pax3 may be susceptible to proteasome-mediated degradation, contrary to the canonical views of the consequences of protein monoubiquitination and the necessity of proteins to be polyubiquitinated to be susceptible to proteasomal degradation.
To examine Pax3 ubiquitination patterns, we sought to uncouple ubiquitination from proteasomal degradation. We included MG132 throughout the experiment in order to allow ubiquitination to progress but prevent any proteasomal degradation. Under those conditions, Pax3 was monoubiquitinated whether the reaction was carried out in the presence of Ub K0 (as expected) or WT ubiquitin (Ub) ( Figure 2C ). These assay conditions resulted in polyubiquitination of p21 CIP1 in the presence of Ub, showing that all components necessary for polyubiquitination were present ( Figure 2C ). Even after purification by Nickel-agarose beads to pull down all ubiquitinated forms of Pax3, only a monoubiquitinated Pax3 was apparent ( Figure S4 ). We then tested directly our hypothesis that a component of the assay system is both responsible for Pax3 ubiquitination and itself susceptible to ubiquitination and proteasomal degradation. We tested this by comparing Pax3 ubiquitination under two conditions. First, we pretreated the ubiquitin ligase fraction with Ub but in the absence of MG132, thus allowing for degradation of any polyubiquitinated proteins generated. Then, for comparison, we pretreated the ubiquitin ligase fraction with Ub K0 to prevent any polyubiquitination of assay components that might then be degraded by the 26S proteasome. Under these two conditions, subsequent addition of Pax3 protein (in the presence of MG132 to prevent degradation of ubiquitinated Pax3) revealed that Pax3 monoubiquitination was enhanced when the reaction components were protected by Ub K0 compared to that seen when the ubiquitin ligase fraction was pretreated with Ub ( Figure 2D ). Furthermore, when reactions were carried out under conditions that permitted the formation of only monoubiquitinated Pax3 but allowed for proteasomal degradation, there was a rapid decline in Pax3 levels ( Figure 2E ). These results again suggest that our in vitro assay most closely parallels the in vivo conditions when components of the in vitro assay are protected against polyubiquitination and degradation. Together, the results strongly suggest that Pax3 undergoes primarily, if not exclusively, monoubiquitination and that, surprisingly, the monoubiquitinated form of Pax3 is the form targeted for proteasomal degradation.
Lysines 475 and 437 Are Important for the Ubiquitination and Degradation of Pax3 To study further the ubiquitination of Pax3, we sought to identify the lysines in the protein that were targets for ubiquitination. Our first clues came from differential susceptibilities to proteasomal degradation of proteins with high homology to Pax3. We compared stabilities of Pax3, Pax7, and Pax3FKHR in pulse-chase experiments in myoblasts ( Figure 3A ). In Pax3FKHR, the C-terminal region of Pax3 is replaced by the C-terminal region of FKHR. While Pax3 degradation was inhibited by MG132, Pax3FKHR protein stability was not affected by the inhibitor, consistent with the resistance of Pax3FKHR to degradation in the cell-free assay even in the presence of Ub Me ( Figure S3B ). Since FKHR itself does not confer protein stability (Matsuzaki et al., 2003) , this result suggests that the region of Pax3 missing from the fusion protein may contain an important ubiquitination site required for the degradation of Pax3. Pax7 was not susceptible to proteasomal degradation in these pulse-chase experiments ( Figure 3A ). We thus focused our attention on lysines in the C-terminal region of Pax3 ( Figure 3B ). Within this region, there is one lysine (lysine 475) specific to Pax3 and another (lysine 437) present in both Pax3 and Pax7 ( Figure 3B ). Replacement of lysine 475 with arginine (mutant termed Pax3 SM ) dramatically reduced the degradation of Pax3 in myoblasts ( Figure 3C ). A double mutant (Pax3 DM ) in which both lysine 475 and lysine 437 were replaced by arginines stabilized Pax3 even further ( Figure 3C ). These results suggest that these two lysines are important for the ubiquitination of Pax3 and for its subsequent degradation, even though lysine 437 does not render Pax7 susceptible to these processes.
Pax3 Monoubiquitination Level Correlates with Pax3 Degradation Rate in Myoblasts
Since Pax3 protein became more stable by the mutation of lysines 475 and 437, we assessed the ubiquitination status of Pax3, Pax3 SM , and Pax3 DM in myoblasts. Western blot analysis of the immunoprecipitated Pax3 proteins was conducted with an antibody (FK-1) that recognizes only polyubiquitinated proteins or an antibody (FK-2) that recognizes both mono-and polyubiquitinated proteins (Fujimuro et al., 1994) . No polyubiquitinated conjugates of any of these proteins were detected with FK-1 ( Figure 4A ). With FK-2, bands corresponding in molecular weight to monoubiquitinated conjugates of each protein were observed. There was less monoubiquitinated Pax3 SM than monoubiquitinated Pax3, and still less monoubiquitinated Pax3 DM ( Figure 4A ). Therefore, mutating these specific C-terminal lysine residues did not abrogate completely the ubiquitination of Pax3, but the relative resistance of the proteins to monoubiquitination paralleled their relative stabilities (compare Figures 4A and 3C ).
To assess quantitatively the level of monoubiquitination of the immunoprecipitated protein, lysates were subjected to Nickel-agarose pull-down to purify ubiquitinated proteins using a histidine-tagged ubiquitin. Immunoblotting of purified proteins revealed single bands corresponding to monoubiquitinated conjugates ( Figure 4B ). By contrast, identical analysis of p21 CIP1 revealed multiple, high-molecular-weight polyubiquitinated conjugates (Figures S5A and S5B) . Quantitation of the level of monoubiquitination of the different forms of Pax3 again showed that Pax3 SM was monoubiquitinated to a lesser extent than was Pax3, and that Pax3 DM was monoubiquitinated even less ( Figure 4B ). As a test of the sufficiency of monoubiquitination to drive Pax3 degradation, the stability of each of the Pax3 mutants was assessed when expressed as fusion proteins with Ub K0 , a modification that does not render protein susceptible to proteasomal degradation nonspecifically (Li et al., 2003) . Both Pax3 SM -Ub K0 and Pax3 DM -Ub K0 were much more susceptible to proteasome-mediated degradation than were the unconjugated forms ( Figure 4C ), supporting the hypothesis that monoubiquitination is sufficient to mediate the degradation of Pax3 proteins.
Lysine 475 Is a Key Residue Representing the Divergent Signature of Protein Stability between Pax3 and Pax7
To examine further whether the difference of a single lysine residue was sufficient to explain the observed differences between Pax3 and Pax7, we introduced a lysine into Pax7 at the residue corresponding to lysine 475 in Pax3 to generate a Pax7 A468K mutant ( Figure 4D ). Unlike WT Pax7, Pax7 A468K was susceptible to proteasomal degradation with similar kinetics as seen for Pax3 ( Figure 4E ). Furthermore, analysis of the ubiquitination status of Pax7 A468K revealed that the protein, like Pax3, became monoubiquitinated in vivo ( Figure 4F ). These results confirm that lysine 475 is a key residue that distinguishes Pax3 from Pax7 and underline differences in these two otherwise highly homologous proteins in terms of protein stability.
Monoubiquitinated Pax3
Associates with the Proteasome Proteasomal degradation generally requires polymeric chains of at least four ubiquitins to allow recognition of the substrate by the proteasome through an array of ubiquitin receptor proteins such as the intrinsic receptor S5a (Thrower et al., 2000) or substrate receptors such as Rad23 (Elsasser and Finley, 2005) . To determine the mechanism by which monoubiquitinated Pax3 is recognized by the proteasome, we first tested for an association between S5a and Pax3 using a pull-down assay, again using p21 CIP1 as a positive control ( Figure S6 ). We were able to pull down Pax3 with S5a protein ( Figure 5A ). Identical studies with the Pax3 mutants, Pax3 SM and Pax3 DM , revealed that the relative levels of these proteins that could be pulled down with S5a directly correlated with their respective levels of monoubiquitination and protein degradation ( Figures 3C, 4A , and 4B).
Since S5a binds selectively to polyubiquitinated proteins (Deveraux et al., 1994; Young et al., 1998) , we looked for a protein that could bridge S5a and monoubiquitinated Pax3. Given the ability of members of the Rad23 family both to bind monoubiquitin and to shuttle ubiquitinated proteins to the proteasome (Bertolaet et al., 2001; Wilkinson et al., 2001) , we tested members of this family as potential mediators of the association of monoubiquitinated Pax3 with S5a. Consistent with previous studies (Hiyama et al., 1999) , Rad23A and Rad23B were pulled down with S5a protein ( Figure 5A) . Interestingly, the amounts of Rad23B, but not Rad23A, that were detected declined in parallel with the amount of Pax3 protein pulled down ( Figure 5A ), suggesting an obligate Pax3 Rad23B binding for association with the proteasome. We also determined whether Pax3 could be pulled down with the ubiquitin-association domain 2 (UBA2) of Rad23B. The relative amount of Pax3 proteins pulled down using the Rad23B UBA2 domain was in the order Pax3 > Pax3 SM > Pax3 DM ( Figure 5B ). These data further support a model of Pax3 being targeted to the proteasome by interactions with Rad23B. We produced recombinant Pax3 and Pax3-Ub proteins and performed in vitro binding assays in order to test the binding between forms of Pax3 and proteins containing UBA domains. Neither Pax3 nor Pax3-Ub bound directly to either S5a or Rad23A, but Pax3-Ub bound to Rad23B ( Figure 5C ). In addition, Pax3 bound weakly and Pax3-Ub bound strongly to the UBA2 domain of Rad23B ( Figure 5C ), suggesting that the Rad23B Pax3 interface involves not only the ubiquitin moiety but also the Pax3 protein itself. These data demonstrate the importance and specificity of Rad23B for the interaction of monoubiquitinated Pax3 with the proteasome.
As an independent test of the hypothesis that the monoubiquitinated form of Pax3 is the primary form that is targeted to the proteasome, we transfected myoblasts with a Pax3 expression construct, performed immunoprecipitation of Pax3 after S5a pull-down, and analyzed the ubiquitination status of the immunoprecipitated Pax3 protein. In cell extracts, a small fraction of the protein was monoubiquitinated and, again, no polyubiquitination could be detected ( Figure 5D ). However, if that extract was first subjected to S5a pull-down, then virtually all of A468K -GFP expression constructs together with a His 6 -tagged ubiquitin expression construct were treated with MG132 for 6 hr. His 6 -tagged ubiquitin conjugates were purified on Nickel-agarose gels and the migration of Pax7 proteins was analyzed by immunoblotting with an anti-GFP antibody. Again, arrows show the positions of Pax7 and monoubiquitinated Pax7 proteins (Pax7-Ub 1 ). Pax7 A468K proteins appeared to be monoubiquitinated.
the immunoprecipitated Pax3 was monoubiquitinated ( Figure 5D ). Therefore, Pax3 proteins that bind to the proteasome are monoubiquitinated, further suggesting that monoubiquitination of Pax3 is required for its degradation by the proteasome. Since S5a exists in both proteasome-bound and free forms (van Nocker et al., 1996) , we assessed whether the Pax3/Rad23B/S5a complex could be copurified with the 26S proteasome. After transfecting myoblasts with Pax3 constructs, we immunoprecipitated the proteasome using a polyclonal antibody directed against the ''core'' 20S proteasome subunits. Rad23B coprecipitated with the proteasome core, with higher levels associated with the proteasome in Pax3-transfected cells compared to controls ( Figure 5E ). In addition, only one form of Pax3 could be detected in association with the proteasome, and this form corresponded to monoubiquitinated Pax3 by molecular weight. These results demonstrate the presence of the trimeric protein complex of S5a/Rad23B/ Pax3-Ub in a proteasomal context. -GFP expression construct were treated with MG132 for 6 hr. Cell extracts were subjected to Rad23B (UBA2)-agarose pull-down and levels of Pax3 proteins were analyzed by immunoblotting with anti-GFP antibody. Pax3 protein levels were determined as the ratio of Pax protein pulled down to Pax protein input relative to Pax3. Error bars represent ± SD. (C) Binding studies between Pax3 or Pax3-Ub and S5a, Rad23A, Rad23B, or Rad23B UBA2. Pax3, Pax3-Ub, Rad23A, and Rad23B were produced as GST fusion proteins. Proteins were purified with glutathione sepharose beads. GST tags of Pax3 and Pax3-Ub were removed by Thrombin treatment. S5a, Rad23A, Rad23B, and Rad23B UBA2-agarose beads were mixed in lysis buffer with Pax3 or Pax3-Ub and washed, and Pax3 proteins were analyzed by immunoblots with anti-Pax3 antibody. (D) Analysis of the ubiquitination status of Pax3 bound to the proteasomal protein S5a. Myoblasts transfected with a Pax3-GFP expression construct were treated with MG132 for 6 hr. Cell extracts were subjected to S5a-agarose pull-down. The resulting purified proteins were then denatured by boiling and subjected to immunoprecipitation with a GFP antibody. As a control, cell extracts were directly denatured and immunoprecipitation with the GFP antibody was conducted. Proteins were analyzed by immunoblotting with anti-GFP and antiubiquitin (FK-2) antibodies. Arrows indicate the positions of Pax3 and monoubiquitinated Pax3 protein.
(E) Immunoprecipitation of the 26S proteasome. Myoblasts transfected with GFP or Pax3-GFP expression constructs were treated with MG132 for 6 hr. Cell extracts were subjected to immunoprecipitation with a 20S core protein antibody. Proteins were analyzed by immunoblotting with an anti-GFP antibody (Pax3), anti-Rad23B antibody (Rad23B), anti-S5a antibody (S5a), anti-S8/Rpt6 antibody (S8), and anti-20S core antibody (20S Core). In control and Pax3-transfected cells, the same amount of 20S proteasome subunits were pulled down as shown with the 20S core antibody. The presence of the 19S proteasome was assessed by the presence of S8/Rpt6 and S5a proteins. Detected Pax3 protein displays a molecular weight consistent with a monoubiquitinated form (arrow).
Rad23B Is Required for Pax3 Association with and Degradation by the Proteasome
To further test the importance of Rad23B for the association of Pax3 with the proteasome, we assessed the binding of Pax3 to S5a in cells with aberrant patterns of expression of Rad23 isoforms. For these studies, we used WT mouse embryonic fibroblasts (MEFs) or MEFS deficient in Rad23A, Rad23B, or both isoforms (''double knockout '' [DKO] ). MEFs were transfected with Pax3 constructs, and extracts were subjected to S5a pulldown assays. Pax3 proteins could be pulled down only in cells expressing Rad23B ( Figure 6A ). No Pax3 was detected in the Rad23B À/À or DKO cells. In addition, when
we assessed the stability of Pax3 proteins in these different cells, Pax3 was degraded only in the cells expressing Rad23B ( Figure 6B ). Overall, these results show that Rad23B plays an essential role in shuttling Pax3 to the proteasome to mediate its degradation.
Functional Significance of the Regulation of Pax3 Stability
Since Pax3 is known to inhibit myogenic terminal differentiation in C2C12 (Epstein et al., 1995) , we hypothesized that the degradation of Pax3 is important for the progression of the myogenic program beyond commitment. To test this hypothesis, we examined the effects of the expression for Pax3 proteins with differential susceptibility to proteasomal degradation (Pax3, Pax3 Figure 7A ). The inhibition of fusion was paralleled by a reduction in expression of markers of terminal myogenic differentiation ( Figure 7B ). Interestingly, when examined by immunofluorescence, the expression patterns of Myosin Heavy Chain and aActinin were mutually exclusive with Pax3 ( Figures 7C  and S7D) , suggesting that the expression of Pax3 maintains myogenic progenitors in an undifferentiated state and that the degradation of Pax3 is essential for myogenic differentiation to occur.
DISCUSSION
Previous results suggested that Pax3 is transiently expressed during satellite cell activation ex vivo and that Pax3 expression corresponded to a highly proliferative state of pre-myoblast cells (Conboy and Rando, 2002) . This report adds to these results by demonstrating that after the peak of protein expression, Pax3 protein level is downregulated as the cells become committed myoblasts and that a further decline is necessary for terminal myogenic differentiation, consistent with previous findings (Epstein et al., 1995) . Similar to the process of melanocyte stem cell differentiation (Lang et al., 2005) , Pax3 protein expression seems to be associated with an intermediate precursor cell of the myogenic lineage. During development, Pax3 is expressed as in myogenic progenitors, and overexpression of Pax3 promotes myogenic commitment of cells in the presomitic paraxial and lateral plate mesoderm (Maroto et al., 1997) . These Pax3-induced progenitors also expressed markers of myogenic differentiation after 5 days in culture, although neither the levels of Pax3 protein nor the uniformity of differentiation were examined (Maroto et al., 1997) . Therefore, Pax3 expression is clearly associated with a highly proliferative undifferentiated progenitor population during development as well, but the regulatory mechanisms that lead to differentiation of Pax3 + cells (including the possible degradation of Pax3 protein) remain to be determined. Genetic studies using reporter genes suggest that Pax3 is expressed in a subset of quiescent satellite cells (Relaix et al., 2006) , whereas it appears that the majority of satellite cells express only Pax7 (Seale et al., 2000) . Pax3 and Pax7 share a very high degree of homology and both are expressed in the myogenic lineage, but they differ both in terms of their patterns of expression and their functionality (Relaix et al., 2004 (Relaix et al., , 2006 . While considerable attention has been directed to patterns of expression through knockin and transgenic studies, which The results of the present study demonstrate an important difference between Pax3 and Pax7 regulation at the level of protein stability. The levels of Pax 3 protein are regulated by ubiquitination and proteasomal degradation, whereas levels of Pax7 protein are not. Remarkably, one amino acid (lysine 475) at the C-terminal region of Pax3 appears to be a critical residue, rendering Pax3 susceptible to ubiquitination and subsequent proteasomal degradation. In Pax7, this residue is an alanine and thus not a target for ubiquitination. However, when this alanine is changed to a lysine, Pax7 becomes susceptible to ubiquitination and proteasomal degradation, further emphasizing the critical importance of lysine 475 for the susceptibility of Pax3 to proteasome degradation. Another lysine in the C-terminal region of Pax3 (lysine 437), which is present also in Pax7, appears also to be important for Pax3 ubiquitination since the mutation of this residue enhances the stability of Pax3 in vivo and in vitro. Furthermore, it is intriguing that while both lysines are critical for Pax3 protein stability, the species detected indicated ubiquitination at only a single residue. However, this is precisely what was observed in initial studies of protein ubiquitination as degradation signals. Chau et al. demonstrated that only two of the 22 lysines in the b-galactosidase protein were targets for polyubiquitination, and that the ubiquitin conjugation at one lysine precluded ubiquitination of the other lysine (Chau et al., 1989) . The ubiquitination of Pax3 could be subject to the same constraints. Lysine 475 or lysine 437 may both be targets for ubiquitination, but the ubiquitination of one may possibly preclude ubiquitination of the other. In fact, the differential patterns of Pax3 and Pax7 ubiquitination likely conform to the N-end rule (Varshavsky, 1997) , in which the minimal requirements for substrate ubiquitination are an appropriate recognition determinant (a ''destabilization signal'') and a sterically accessible lysine. Accordingly, the relevant ubiquitin-conjugating enzyme might recognize the critical determinant and the sterically accessible lysine of Pax3, but comparable combinations do not exist in Pax7, as the ubiquitination depends stringently upon the spatial proximity of the destabilizing signal and the mobility of the region containing the lysine .
In addition to the intriguing finding that Pax3, but not Pax7, is regulated by ubiquitination is the even more unexpected set of results suggesting that it is a monoubiquitinated form of Pax3 that is targeted for proteasomal degradation. Monoubiquitination is known to target membrane proteins for endocytosis and lysosomal degradation or to be a posttranslational modification that is involved in transcriptional regulation (Hicke, 2001) . Monoubiquitination of p53 protein is interpreted as a nuclear export signal (Li et al., 2003) . Heretofore, there have been no reports of monoubiquitination being a signal for proteasomal degradation. However, although polyubiquitination of a target protein allows for efficient recognition by the proteasome and subsequent destruction (Thrower et al., 2000) , localization of a protein to the proteasome, even independent of ubiquitination, is sufficient to permit proteasomal degradation (Janse et al., 2004) . For example, ornithine decarboxylase is degraded by the proteasome without ubiquitination (Coffino, 2001 ). Thus, a mechanism that facilitates shuttling or efficient binding of a protein to a proteasomal subunit appears to be sufficient to target a protein for proteasomal degradation. Our results are consistent with a model whereby monoubiquitinated Pax3, but not nonubiquitinated Pax3, is targeted to the proteasome for degradation in a process mediated by binding of monoubiquitinated Pax3 to S5a via Rad23B ( Figure S8 ). We cannot rule out the possibility that some low levels of polyubiquitinated forms are generated in vivo and rapidly degraded. However, under every experimental condition tested, nonubiquitinated and monoubiquitinated forms of Pax3 were clearly present, easily detected, and the predominant species.
Many ubiquitin-binding proteins have been identified and each of them displays ubiquitin-binding domains (UBDs) that are structurally diverse (Hicke et al., 2005) . UBDs can interact directly with monoubiquitin and/or polyubiquitin chains. These different ubiquitin receptors exhibit a remarkable specificity for their polyubiquitinated proteins (Verma et al., 2004) , and therefore these receptors constitute an important aspect of substrate selectivity of the UPS. Our data suggest that ubiquitin-binding proteins may also bind to monoubiquitinated proteins and mediate their binding to the proteasome for degradation. Monoubiquitinated Pax3 does not bind to S5a directly but rather indirectly via Rad23B. Interestingly, we show that Rad23B, but not Rad23A, binds monoubiquitinated Pax3, demonstrating a clear specificity for the substrate between the two Rad23 isoforms. Although Rad23B UBA2 also binds to nonubiquitinated Pax3 (although less strongly than to monoubiquitinated Pax3), only monoubiquitinated Pax3 binds to full-length Rad23B and is associated with the proteasome. These results suggest that the interaction between Pax3 and Rad23B alone is not sufficient and requires the presence of the ubiquitin to strengthen the interaction and promote targeting to the proteasome. As Rad23B has also been shown to have a weak interaction with ubiquitin monomer (Raasi et al., 2004) , it is possible that it is the combination of binding to Pax3 and ubiquitin that mediates the targeting of monoubiquitinated Pax3 to the proteasome by Rad23B.
We were unable to detect any polyubiquitination of Pax3 under any in vivo or in vitro conditions. Polyubiquitination requires E1, E2, and E3 ubiquitin ligases, whereas monoubiquitination of proteins requires E1 and E2 activities only (Ciechanover et al., 2000) . The molecular mechanism leading to the monoubiquitination of Pax3 remains unknown. It may involve only E1 or E2 ubiquitin ligases. However, as Rad23B is a negative regulator of polyubiquitin chain formation (Ortolan et al., 2000) , Pax3 ubiquitination may involve E1, E2, and E3 ubiquitin ligases with Rad23B preventing the formation of a polyubiquitin chain. Thus, Rad23B might be important not only to bring monoubiquitinated Pax3 to the proteasome but also to regulate the ubiquitination reaction.
In summary, our results add to the growing list of the pleiotropic effects of ubiquitination of regulating protein stability and suggest that monoubiquitination of a protein may be a signal for proteasomal degradation. The mechanism described here for regulating Pax3 protein levels is likely to underlie differences in the patterns of expression between Pax3 and Pax7. These results provide new insights as to the molecular mechanisms regulating Pax3 in muscle stem cells and might also shed light on the regulation of Pax proteins in other stem cell lineages.
EXPERIMENTAL PROCEDURES
Details about cDNA cloning and constructs and about standard methodologies (immunofluorescence microscopy, immunoblotting, immunoprecipitation, FACS, quantitative RT-PCR) can be found in the Supplemental Data available with this article online.
Constructs and Cell Lines
The ts20b and H38.5 cell lines were provided by Dr. H.L. Ozer (UMDNJ), the Pax3FKHR and Pax7FKHR mammalian expression constructs were provided by Dr. F. Barr (U. Penn), the Ub K0 and Ub mammalian expression constructs were provided by Dr. W. Gu (Columbia University), and the His 6 -tagged ubiquitin mammalian expression vector was provided by Dr. D. Bohmann (University of Rochester). WT, Rad23A
, and DKO MEFs were provided by Dr. Jan H.J. Hoeijmakers (Erasmus Medical Center). pGEX-hHR23A was provided by Dr. K.J. Walters (University of Minnesota). pGEX-mHR23B was provided by Dr. W.J. Lennarz (Stony Brook university).
Satellite Cell Isolation, Myoblast Cultures, and Single-Fiber Isolations Satellite cells were purified from bulk fibers and activated in vitro as described previously (Conboy and Rando, 2002; Conboy et al., 2003) . Myoblast cultures were maintained as proliferating mononucleated cells or were induced to differentiate as previously described (Quach and Rando, 2006) . Single myofibers and associated satellite cells from extensor digitorum longus muscles were prepared as described previously (Rosenblatt et al., 1995) .
In Vivo Protein Stability Assay C2C12 myoblasts were transfected with pEGFP-N3-Pax3, pcDNA3.1-Pax3FKHR, pEGFP-N3-Pax3 SM , pEGFP-N3-Pax3 DM , pEGFP-N3-Pax7, and pEGFP-N3-Pax7 A468K plasmids with pDsRed2-N1 plasmid as a control. Cycloheximide (CHX) (5 mM) and either dimethylsulfoxide (DMSO) or MG132 (10 mM) were added 24 hr after transfection, cells were harvested at each time point (0, 6, 12, and 24 hr), and lysates were analyzed by Western blots. The ts20b and H38-5 cells were used in the same way except that they were transfected with only pEGFP-N3-Pax3 and pDsRed2-N1 expression vectors. Cells were treated with CHX and placed at 34 C or 40 C. MEFs were transfected with pEGFP-N3-Pax3 and pDsRed2-N1 and were treated with CHX. Primary myoblasts were treated with DMSO or MG132 (5, 7.5, or 10 mM) for 6 hr. Cells were harvested and lysates were analyzed by Western blots. The films were scanned and quantified with ImageJ (http:// rsb.info.nih.gov/ij/).
Cell-free Coupled Ubiquitination/Degradation and Ubiquitination Assays
Coupled ubiquitination/degradation assays were performed on Pax and p21 CIP1 proteins produced with Promega TNT quick coupled transcription/translation system. The reaction mix contained 2 ml of in vitrolabeled [ 35 S] Pax and p21 CIP1 protein and 2 ml of a 53 stock reaction mix (50 mM Tris-HCl pH 7.6, 5 mM MgCl 2 , 2 mM ATP, 10 mM phosphocreatine, 17.5 U/ml phosphocreatine kinase, 1 mM ubiquitin aldehyde, 0.8 mg ubiquitin-conjugating enzyme fractions [Sigma] , and 50 nM 26S proteasome [Biomol International]) . Following incubation at 30 C for 0, 1, 2, 4, and 6 hr, reactions were stopped by addition of sample buffer and subjected to SDS-PAGE followed by autoradiography. Ubiquitination assays were performed in the same way at 37 C in the presence of MG132 either with Ub or Ub K0 (Boston Biochem) and without 26S
proteasome. In the case of proteasomal pretreatment, the reaction mix without labeled Pax3 proteins was incubated for 6 hr at 37 C. After treatment, 10 mM MG132 and 10 ml of in vitro-labeled [
35 S] Pax protein were added to the reaction mix and incubated at 37 C. Ubiquitinconjugating enzyme fractions (Sigma) were pretreated with 1 mg of Ub or Ub K0 (Boston Biochem) in reaction mix (50 mM Tris-Cl pH 7.6, 5 mM MgCl 2 , 2 mM ATP, 10 mM phosphocreatine, 17.5 U/ml phosphocreatine kinase), 1 mM ubiquitin aldehyde, and 50 nM 26S proteasome (Biomol International) at 37 C for 4 hr. Recombinant Pax3 protein, 25 mg of Ub, and 26S proteasome were added and incubated at 37 C for 6 and 18 hr. Reactions were stopped by addition of sample buffer and subjected to SDS-PAGE followed by transfer and Western blot analysis.
In Vivo Ubiquitination Myoblasts were transfected as described above with pEGFP-N3-Pax3, pEGFP-N3-Pax3 SM , pEGFP-N3-Pax3 DM , pEGFP-N3-Pax7, or pEGFP-N3-Pax7 A468K constructs alone or with His 6 -tagged ubiquitin construct. Transfected cells were pretreated with 10 mM MG132 for 6 hr to block Pax3 degradation, and extracts were prepared in lysis buffer containing 100 mM MG132, 20 mM ubiquitin aldehyde, and 100 mM N-ethylmaleimide (NEM, Sigma). Lysates were denatured by boiling for 5 min in the presence of 0.1% SDS. Immunoprecipitation was carried out by adding 10 mg of anti-GFP monoclonal antibody (Santa Cruz Biotechnology). For cotransfection of the Pax3 and His 6 -tagged ubiquitin expression vectors, cells were treated with 10 mM MG132 for 6 hr and extracts were prepared in CelLytic M reagent (Sigma) lysis buffer containing 100 mM MG132, 20 mM ubiquitin aldehyde. His-tagged proteins were purified on Nickel affinity gel using His-Select M affinity Capture Kit (Sigma) according to the manufacturer's instructions. Immunoprecipitated and purified proteins were analyzed by Western blotting using an anti-GFP monoclonal antibody and anti-ubiquitin antibodies (FK-1 and FK-2).
S5a and Rad23 Pull-Down Assays Myoblasts were transfected as described above with pEGFP-N3-Pax3, pEGFP-N3-Pax3 SM , or pEGFP-N3-Pax3 DM constructs. MEFs were transfected with pEGFP-N3-Pax3. Transfected cells were pretreated with 10 mM MG132 for 6 hr to block protein degradation and extracts were prepared in lysis buffer containing 100 mM MG132, 20 mM ubiquitin aldehyde, and 100 mM NEM. Pull-down was carried out by adding 10 ml of Agarose S5a or Agarose Rad23B UBA2 (Biomol International). After S5a pull-down, the beads were washed three times, resuspended in lysis buffer containing 0.1% SDS, and denatured by boiling for 5 min.
Recombinant Proteins and In Vitro Protein-Binding Assay
Recombinant Pax3, Pax3-Ub WT , Rad23A, and Rad23B were produced as GST-fusion proteins in E. coli BL21, extracted in MT-PBS (10% glycerol, 1 mM DTT, 0.5 mM PMSF) containing 1% Triton X-100, and purified on glutathione-Sepharose resin (GE). GST tags were excised with Thrombin (GE) and PreScission (GE) (5 U/ml for 6 hr at room temperature). S5a protein and Rad23B UBA2 beads (10 ml) were incubated with the same amount of Pax3 and Pax3-Ub protein product at room temperature for 1 hr in lysis buffer used for S5a pull-down with cell lysates. In the case of Rad23A and Rad23B pull-down, GST fusion proteins were extracted as described above and incubated with the same amount of Pax3 and Pax3-Ub WT . Beads were washed and bound proteins were eluted with 20 ml of SDS loading buffer.
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